Shire (SHPG) Given a $225.00 Price Target at Cowen

Shire (NASDAQ:SHPG) has been given a $225.00 price target by equities research analysts at Cowen in a research note issued on Friday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Cowen’s target price would indicate a potential upside of 43.05% from the company’s previous close.

Several other brokerages have also recently commented on SHPG. Piper Jaffray Companies reiterated a “hold” rating on shares of Shire in a research note on Wednesday. Cantor Fitzgerald set a $222.00 price objective on shares of Shire and gave the company a “buy” rating in a research note on Wednesday. Liberum Capital reiterated a “hold” rating on shares of Shire in a research note on Wednesday, December 20th. Royal Bank of Canada reiterated a “buy” rating and issued a $213.00 price objective on shares of Shire in a research note on Monday, October 2nd. Finally, ValuEngine cut shares of Shire from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and eight have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $212.18.

Shares of Shire (NASDAQ SHPG) opened at $157.29 on Friday. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55. Shire has a 52 week low of $137.17 and a 52 week high of $192.15. The company has a market cap of $47,700.00, a PE ratio of 29.62, a P/E/G ratio of 0.85 and a beta of 1.59.

Shire (NASDAQ:SHPG) last announced its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.81 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.64 by $0.17. Shire had a net margin of 10.95% and a return on equity of 14.41%. The firm had revenue of $3.70 billion during the quarter. During the same quarter last year, the business earned $3.17 EPS. The firm’s revenue for the quarter was up 7.1% on a year-over-year basis. research analysts forecast that Shire will post 15 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Steward Partners Investment Advisory LLC acquired a new position in Shire during the third quarter worth about $159,000. Sterling Capital Management LLC raised its position in Shire by 26,182.4% during the third quarter. Sterling Capital Management LLC now owns 474,397 shares of the biopharmaceutical company’s stock worth $72,649,000 after acquiring an additional 472,592 shares during the last quarter. Afam Capital Inc. raised its position in Shire by 3.0% during the third quarter. Afam Capital Inc. now owns 30,761 shares of the biopharmaceutical company’s stock worth $4,711,000 after acquiring an additional 882 shares during the last quarter. Neuberger Berman Group LLC raised its position in shares of Shire by 16.4% in the third quarter. Neuberger Berman Group LLC now owns 21,789 shares of the biopharmaceutical company’s stock valued at $3,337,000 after buying an additional 3,076 shares during the last quarter. Finally, Lumbard & Kellner LLC raised its position in shares of Shire by 46.9% in the third quarter. Lumbard & Kellner LLC now owns 26,685 shares of the biopharmaceutical company’s stock valued at $4,087,000 after buying an additional 8,515 shares during the last quarter. Institutional investors own 20.19% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Shire (SHPG) Given a $225.00 Price Target at Cowen” was originally posted by American Banking and Market News and is owned by of American Banking and Market News. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/05/shire-shpg-given-a-225-00-price-target-at-cowen.html.

Shire Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.